Takeda Pharmaceutical (TAK) Income from Non-Controlling Interests (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Income from Non-Controlling Interests of $376434.2 for Q2 2026, up 51.3% year-over-year from $248799.8 in Q2 2025, and up 159.03% quarter-over-quarter from -$637655.0 in Q1 2026.
Takeda Pharmaceutical (TAK) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $376434.2 for Q2 2026.
- In Q2 2026, Income from Non-Controlling Interests rose 51.3% year-over-year to $376434.2; the TTM figure through Jun 2026 stood at -$2.3 million (up 5.69% YoY), while the FY2026 annual figure was $1.8 million, up 24.26% from the prior year.
- Income from Non-Controlling Interests for Q2 2026 stood at $376434.2, up from -$637655.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $376434.2 in Q2 2026, with the low at -$1.4 million in Q3 2025.
- The 5-year median for Income from Non-Controlling Interests is -$391968.8 (2022), against an average of -$352612.9.
- The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests sank 856.34% in 2023, then jumped 308.17% in 2024.
- Takeda Pharmaceutical's Income from Non-Controlling Interests stood at $155723.0 in 2022, then sank by 544.66% to -$692442.5 in 2023, then rose by 5.01% to -$657777.5 in 2024, then rose by 1.21% to -$649790.1 in 2025, then surged by 157.93% to $376434.2 in 2026.
- Business Quant data shows TAK's Income from Non-Controlling Interests at $376434.2 in Q2 2026, -$637655.0 in Q1 2026, and -$649790.1 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 376,434.15 |
| Mar 31, 2026 | -637,655.00 |
| Dec 31, 2025 | -649,790.06 |
| Sep 30, 2025 | -1.36 Mn |
| Jun 30, 2025 | 248,799.82 |
| Mar 31, 2025 | -655,461.14 |
| Dec 31, 2024 | -657,777.46 |
| Sep 30, 2024 | -1.34 Mn |
| Jun 30, 2024 | 327,618.88 |
| Mar 31, 2024 | -674,781.42 |
| Sep 30, 2023 | -692,442.51 |
| Jun 30, 2023 | 80,266.13 |
| Dec 31, 2022 | 155,723.01 |
| Sep 30, 2022 | -72,405.39 |
| Jun 30, 2022 | 54,126.69 |
| Mar 31, 2022 | -146,282.58 |
| Dec 31, 2021 | 448,660.06 |
| Sep 30, 2021 | 281,603.63 |
| Jun 30, 2021 | 392,805.78 |
| Mar 31, 2021 | 434,585.04 |